Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Victorian Clinical Genetics Services, |
RCV001090000 | SCV001245041 | likely pathogenic | 3-hydroxy-3-methylglutaryl-CoA synthase deficiency | 2019-01-07 | criteria provided, single submitter | clinical testing | A heterozygous missense variant, NM_005518.3(HMGCS2):c.905C>T, has been identified in exon 5 of 10 of the HMGCS2 gene. The variant is predicted to result in a moderate amino acid change from threonine to isoleucine at position 302 of the protein (NP_005509.1(HMGCS2):p.(Thr302Ile)). The threonine residue at this position has high conservation (100 vertebrates, UCSC), and is located within the hydroxymethylglutaryl-coenzyme A synthase C terminal domain. In silico predictions for this variant are consistently pathogenic (Polyphen, SIFT, CADD, Mutation Taster). The variant is absent in the gnomAD population database, and has not been previously reported in clinical cases. Analysis of parental samples indicated this variant was maternally inherited. Following multidisciplinary clinical review of this case, this variant was determined to be highly concordant with the phenotypic presentation of the patient. Based on the information available at the time of curation, this variant has been classified as LIKELY PATHOGENIC. |